Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

This is a single arm prospective trial in patients with newly-diagnosed advanced renal cell cancer (RCC) who were scheduled for sunitinib therapy and utilized an extensive panel of quantitative metrics on baseline and interim FDG PET/CT to evaluate the predictive utility of each of these measurements.

The objectives were to evaluate the FDG PET/CT measurement parameters for prediction of prognosis after sunitinib therapy in patients with RCC using histopathologic (post-therapy nephrectomy) or clinical follow-up for validation.

Inclusion Criteria:- Measurable disease by RECIST criteria

• Pathologic diagnosis of renal cell cancer
• Advanced (stage IV) renal cell cancer
• Karnofsky performance status of (KPS>70)
• Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot complete a PET/CT scan.
• Pregnant women.
• Healthy volunteers.
• Patients participating in other research protocols will be excluded from this study.
• Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.